(secondQuint)Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer.

 Japanese phase II study of S-1 in cervical cancer suggested promising response rate and good tolerability.

 Since recommended chemotherapy for metastatic or recurrent cervical carcinoma is either single-agent Cisplatin or Cisplatin-based combination chemotherapy, this is designed to evaluate the efficacy and safety of S-1 in combination with Cisplatin compared with single-agent Cisplatin.

.

 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer@highlight

This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.

